With the American Society of Clinical Oncology Annual Meeting 2021 now in full swing, there is more than imaginable data being put out on the table. DelveInsight picked a few of the most crucial abstracts that have the potential to impact the Squamous Cell Carcinoma space. Have a look here.
Abstract Number: 4012: Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma: BeiGene
On 4th June 2021, BeiGene has presented Phase III efficacy results of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second-Line Treatment in Patients with Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma.
Among the enrolled patients, Of these 157 patients (tisle [n=89], ICC [n=68]) had vCPS ≥10% (PD-L1+ population). The study has met its primary endpoint: tisle clinically and significantly improved OS vs ICC in the ITT population (median OS: 8.6 vs 6.3 m). Tisle also demonstrated significant improvement in OS vs ICC in the PD-L1+ population (median OS: 10.3 vs 6.8 m). The survival benefit was consistently observed across pre-defined subgroups, including baseline PD-L1 status and region. Treatment with tisle was also associated with a higher ORR (20.3% vs 9.8%) and a more durable response (median DoR: 7.1 vs 4.0 m) than ICC in the ITT population. Fewer pts had ≥Grade 3 (46% vs 68%) treatment-emergent adverse events with Tislelizumab vs ICC.
Expert Views “Tislelizumab demonstrated statistically significant and clinically meaningful improvement in OS vs ICC in pts with advanced or metastatic ESCC who had disease progression during or after first-line systemic therapy”. These results signify that Tislelizumab represents a potential new second-line treatment option for patients with advanced or metastatic Esophageal Squamous Cell Carcinoma.
There is a lot more! Know more of DelveInsight’s take and thoughts on different indications and abstracts being presented at ASCO21. Join us here.
